Of note, PRMT5 inhibition with GSK3326595 or EPZ015666 (another PRMT5 inhibitor acting in a non-SAM-competitive but peptide substrate-competitive manner) also resulted in remarkably reduced cell proliferation in MCL cell lines (Supplementary Fig. S1c, d). This evidence concerns the gene PRMT5 and mantle cell lymphoma.